Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Trisalus Life Sciences Inc (TLSI)

Trisalus Life Sciences Inc (TLSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 242,772
  • Shares Outstanding, K 61,306
  • Annual Sales, $ 45,150 K
  • Annual Income, $ -39,230 K
  • EBIT $ -27 M
  • EBITDA $ -25 M
  • 60-Month Beta 0.54
  • Price/Sales 5.54
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.16
  • Number of Estimates 1
  • High Estimate $-0.16
  • Low Estimate $-0.16
  • Prior Year $-0.33
  • Growth Rate Est. (year over year) +51.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.61 +14.68%
on 03/30/26
4.85 -14.64%
on 03/09/26
-0.33 (-7.28%)
since 03/06/26
3-Month
3.61 +14.68%
on 03/30/26
6.33 -34.60%
on 01/15/26
-2.00 (-32.57%)
since 01/08/26
52-Week
3.42 +21.05%
on 08/12/25
7.95 -47.92%
on 12/22/25
-1.35 (-24.59%)
since 04/08/25

Most Recent Stories

More News
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to...

TLSI : 4.14 (+4.55%)
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to...

TLSI : 4.14 (+4.55%)
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance

Reports $13.2 million i n Revenue in the Fourth Quarter, $45.2 million for Full-Year of 2025, Representing increases of 60% and 53%, respectively, Versus the Prior Year Periods...

TLSI : 4.14 (+4.55%)
TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call

Conference Call and Webcast Scheduled for Thursday, March 5, 2026 at 4:30 PM

TLSI : 4.14 (+4.55%)
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies...

TLSI : 4.14 (+4.55%)
TriSalus Life Sciences Proposes Public Offering

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies...

TLSI : 4.14 (+4.55%)
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies...

TLSI : 4.14 (+4.55%)
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance

Fourth quarter 2025 revenue of approximately $13.2 million, Up 60% Year-Over-Year Full-year 2025 revenue growth of approximately 53% exceeded 2025 guidance ...

TLSI : 4.14 (+4.55%)
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients...

TLSI : 4.14 (+4.55%)
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™

TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the launch...

TLSI : 4.14 (+4.55%)

Business Summary

TriSalus Life Sciences Inc. is an oncology company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors. TriSalus Life Sciences Inc., formerly known as MedTech Acquisition Corporation, is based in CHICAGO.

See More

Key Turning Points

3rd Resistance Point 4.44
2nd Resistance Point 4.33
1st Resistance Point 4.23
Last Price 4.14
1st Support Level 4.02
2nd Support Level 3.91
3rd Support Level 3.81

See More

52-Week High 7.95
Fibonacci 61.8% 6.22
Fibonacci 50% 5.68
Fibonacci 38.2% 5.15
Last Price 4.14
52-Week Low 3.42

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.